ROS1 and adenocarcinoma: Of note, we found that three of five ROS1 fusion–positive patients harbored concurrent actionable oncogenic somatic mutations of EGFR, PIK3CA, or KRAS. A 65-year-old woman who had never smoked had adenocarcinoma harboring SLC34A2-ROS1 as well as EGFR (L858R) and PIK3CA (E542K) mutations.